Tuesday 28 June 2016

Dilated Cardiomyopathy Therapeutics Market to Decline to US$328.6 mn by 2020 owing to Side Effects of DCM Drugs

Transparency Market Research has published a new report on the global dilated cardiomyopathy therapeutics market. As per the report, the global dilated cardiomyopathy therapeutics market is predicted to decline at a CAGR of -7.0% from 2014 to 2020.The report, titled ‘Dilated Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,’ states that the global market was valued at US$651.0 mn in 2013 and is expected to reach US$328.6 mn by 2020. Factors such as the introduction of gene and stem cell therapies for DCM and the side effects of DCM drugs are expected to restrain the global dilated cardiomyopathy therapeutics market in the years to come.

Get Free Sample Research Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2293
 
Heart failure is primarily caused by dilated cardiomyopathy (DCM). DCM commonly develops in people aged between 20 years and 60 years. DCM is one of the primary factors, which indicates the need of heart transplantation. Approximately 30% to 40% of people genetically inherit DCM. Factors such as thyroid disorders, diabetes, a viral infection in the heart valve, and alcoholism could cause DCM. As per the Pediatric Cardiomyopathy Registry, dilated cardiomyopathy affects 6 out of 1 million children. DCM is commonly diagnosed in young children, the common diagnosis age being 2 years.

The global dilated cardiomyopathy therapeutics market is segmented on the basis of region and drug class. Some of the commonly used drug classes in DCM treatment are aldosterone antagonists, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and beta blockers. In 2013, the angiotensin II receptor blockers (ARBs) segment held the largest share in the global dilated cardiomyopathy therapeutics market. In 2013, the beta blockers segment was the second largest segment in the global dilated cardiomyopathy therapeutics market.

The increasing incidence of congestive heart failure is expected to drive the global dilated cardiomyopathy therapeutics market in the coming few years. DCM accounts for 30% to 40% of congestive heart failure cases every year, reports suggest. Considering the increasing incidence of congestive heart failure, leading players have started initiating many clinical trial studies for DCM. Going forward, a global rise in the number of heart failure cases is expected to increase the demand for effective treatments. This is expected to drive the global dilated cardiomyopathy therapeutics market in the near future. The global market is expected to be hampered by the rising availability of implantable devices and the side effects of DCM drugs.  

Based on geography, the global dilated cardiomyopathy therapeutics market is divided into Asia Pacific, Europe, North America, and Rest of the World. In 2013, in terms of revenue, North America held a massive share in the global dilated cardiomyopathy therapeutics market due to the increasing acceptance of branded drugs and the increasing incidences of congestive heart failure here.

Some of the key companies operating in the global dilated cardiomyopathy therapeutics market are Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and AstraZeneca plc.

Full Research Report on Global Dilated Cardiomyopathy Therapeutics Market: 
http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html

Tuesday 21 June 2016

Prescription Hair Loss and Hair Removal Drugs Market Technological Breakthroughs


Prescription Hair Loss and Hair Removal Drugs Market

The market for prescription hair loss and hair removal drugs is expanding day by day as changing lifestyle is leading to excessive hair problems. Hair loss drugs market targets men more than women, as the problem is more persistent in males. The majorly prescribed hair loss drugs are:
  • Finasteride: The Food and Drug Administration approved this drug for treating men with hair loss. The drug is reported to slow down hair loss in 88% of the men and stimulate hair re-growth in about 66% of the men.
  • Corticosteroids: If hair loss is due to inflammation then corticosteroid drugs are injected in the scalp. These drugs help in stopping inflammation and are majorly prescribed for patients suffering from alopecia areata.

Prescription Hair Loss and Hair Removal Drugs Market: Segmentation

On the other hand, the hair removal drugs market is majorly focused on females than the male population. All the drugs used for hair removal are either anti-androgens or androgen inhibitors. Androgen is the hormone responsible for excessive hair growth. This market is primarily divided into the following segments:
  • Oral contraceptive pills or birth control pills: For women whose hair growth is related to hormonal problems mostly due to aspolycystic ovary syndrome, treatment includes oral contraceptive pills as these pills reduce the level of androgen. The pills which are generally recommended contain ethinylestrodiol (oestrogen) and antiandrogenic progesterone. In addition, these contraceptives also include cyproterone acetate, drospirenone or dienogest.
  • Hair removal drugs: Prescription hair removal drug market consists of the following drugs:
  • Vaniqa: Vaniqua is the only prescription hair loss medication approved by the Food and Drug Administration that reduces growth of unwanted hair on face and body
  • Spironolactone: Spironolactone or aldactone is majorly used to treat excessive body hair in U.S. and is prescribed for patients suffering from hormonal condition hirsutism
  • Flutamide: Flutamide is an effective drug used for hampering growth of excess body and facial hair
  • Finasteride: Finasteride, also known as Propecia or Proscar, works by blocking the conversion of testosterone into dihydrotestosterone, the hormone responsible for stimulating growth in hair follicles on the body
  • Ketoconazole: This is a relatively new drug in the market and is used to control excessive hair growth on the body during hormonal imbalance
A new anti-androgen drug Fluridil has also been developed for treating hyperandrogenic skin syndromes such as hirutism. The clinical study is performed for three months to evaluate the efficacy and safety of 2% fluridil gel in female patients. The results of the study have shown that 2% fluridil gel is an effective and safe method to treat hirsutism.

Prescription Hair Loss and Hair Removal Drugs Market: Geographical Dynamics

The market of North America leads the global market for prescription hair loss and hair removal drugs market followed by the market of Europe due to changing lifestyle and increasing smoking and alcohol consumption leading to hormonal problems in females. According to the Washington Post, hair loss sufferers in America spend more than 3.5 billion dollars a year to treat their hair loss. The market of Asia-Pacific is also growing at a fast pace due to increasing divergence towards the western culture. China is a major revenue generating market for prescription hair loss and hair removal drugs. The major restraint the market is facing currently is the side effects caused by these drugs. Some of the drugs are reported to cause irritation and redness of skin, moods swings and changes in menstrual cycle in some patients.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Full Research Report on Global Prescription Hair Loss and Hair Removal Drugs Market: 
http://www.transparencymarketresearch.com/prescription-hair-loss-hair-removal-drugs-market.html

Monday 20 June 2016

Systemic Antiviral Pharmaceuticals Market - Global Industry Research 2016 to 2023

Global Systemic Antiviral Pharmaceuticals Market

Antiviral drugs are a class of medication that inhibits the development of infection causing viruses. Like antibiotics, specific antiviral drugs are used against specific viruses. As viruses share most of the metabolic processes with the host cell, it is difficult to commercialize new medications that are selective in action. The presently available antiviral agents either act as DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, immunomodulators, neuraminidase inhibitors or integrase strand transfer inhibitors. 

The currently available antiviral drugs target four main kinds of viruses:
  • Herpes
  • Hepatitis
  • Influenza
  • Human Immunodeficiency Virus (HIV)
Global Systemic Antiviral Pharmaceuticals Market: Segmentation

Antiviral drugs can be administered by various methods such as topical or local application, systemic delivery, controlled delivery and targeted delivery. Systemic drug delivery is relatively safe and effective for the treatment than topical agents. In recent times, systemic delivery method is gaining attention owing to its higher therapeutic efficacy and bioavailability. The demand for products with systemic application is high especially in the treatment for chronic viral infections such as hepatitis and HIV infection.

Based on the class of antiviral drugs, the global systemic antiviral pharmaceuticals market is segmented into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, immunomodulators, interferon, neuraminidase inhibitors and integrase strand transfer inhibitors. Increasing resistance to M2 inhibitors has shifted the focus towards neuraminidase inhibitors for the treatment of influenza. Neuraminidase inhibitors class of drugs includes Oseltamivir and Zanamivir which are administered through systemic route. Herpes virus can be treated using medications such as Acyclovir, Brivudin, Cidofovir, Famciclovir, Fomivirsen, Foscarnet, Ganciclovir, Penciclovir, Valacyclovir, Vidarabine and Valganciclovir. Treatment for hepatitis includes administration of either or combination of the following medications:
  • Interferons
  • Ribavarin
  • Nucleoside analogues such as Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine and Tenofovir
  • Protease inhibitors such as Boceprevir, Telaprevir,
Based on the disease type, the global systemic antiviral pharmaceuticals market can be analyzed as herpes, hepatitis, influenza and HIV infection. Recent advancements in the field of antiviral treatment for herpes infection have inclined the ophthalmologists to treat severe ocular infection caused by herpes virus. In addition, the acute retinal necrosis (ARN) syndrome caused by herpes virus and retinal infection caused by cytomegalovirus is also treated using systemic antiviral drugs. Vidarabine, Acyclovir, Ganciclovir, and Foscarnet are the four major systemic antivral drugs used in the treatment of ophthalmic infections. Rising incidence of herpes virus infections, as well as the rising epidemic of HIV infections has led to increase in ophthalmic infections which drive the demand for systemic antiviral pharmaceuticals.

Global Systemic Antiviral Pharmaceuticals Market: Geographical Dynamics

The demand for systemic antiviral pharmaceuticals is high in regions with high prevalence of herpes, influenza, hepatitis and HIV infection. According to World Health Organization (WHO), worldwide 35.3 million people were living with HIV infection at the end of 2012. The prevalence is high in the African region where nearly one in 20 adults is living with HIV infection. Further, the prevalence of herpes simplex virus type 2 is high in Africa, North America and some parts of Asia-Pacific. Early and effective treatment is therefore the primary need in these regions. Hence, the demand for systemic antiviral pharmaceuticals will increase with growing incidence of viral infections.

Some of the major players in the systemic antiviral pharmaceuticals market are GlaxoSmithKline plc, Bristol-Myers Squibb, Gilead Sciences, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Boehringer Ingelheim, Abbott Laboratories and Merck & Co., Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Full Research Report on Global Systemic Antiviral Pharmaceuticals Market: 
http://www.transparencymarketresearch.com/systemic-antiviral-pharmaceuticals-market.html

Thursday 16 June 2016

Sperm Bank Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024


Global Sperm Bank Market: Overview and Dynamics

The global market for sperm banks has been witnessing increasing growth since the last few recent years, primarily owing to the surge in social acceptance and awareness among the general population. Rise in the number of young sperm donors, legalization of and increase in same-sex marriages, various technological advancements in the field of assistive reproduction, and strong support on the part of governments toward donor offspring and sperm donors are also projected to boost the sperm bank market. However, this market continues to be challenged by the negative mindset toward sperm donation, high cost of artificial insemination and assistive reproduction, and several government regulations in developing and underdeveloped countries.


Sperm donors can be of several types: Directed donor, client donor, anonymous donor, and known donor. Sperm banks offer a range of services such as sperm storage, genetic consultation, sperm donations, and semen analysis for a variety of end users such as pre-vasectomy patients, police officers, high-impact athletes, cancer patients, military personnel, firefighters, and transgender people.

The report on the global sperm bank market offers clients an in-depth assessment of the emergence, popularity, need, and forecast of sperm banks across the globe. Various factors driving the demand for sperm banks, those that act as impediments to the market growth, and several policies and laws impacting sperm donation as a service have been carefully studied in the report. The research also highlights the present status of the vendor landscape, identifying the major players competing at a global level and evaluating their performance over the years.

Global Sperm Bank Market: Region-wise Outlook

The global sperm bank market has been segmented on the basis of geography into North America, Europe, Asia Pacific, and Rest of the World. Considering that North America has the highest number of sperm banks with the highest number of licensed labs, this regional market for sperm banks is one of the largest in the world. Other factors such as the availability of advanced assisted reproductive technologies, higher disposable income and spending on health care, growing awareness among the general population, and high rate of miscarriages have also significantly contributed to the growth of the sperm bank market in North America.

Europe is a growing market for sperm banks given the surging demand for the same. However, the high unmet need is presently the only lucrative attraction for market players in the region, since there is a severe shortage of sperm donors as compared to the increasing demand. Countries such as the U.K. have been investing in new and innovative advertising plans to increase awareness among the male population in the country and encourage them to actively participate in sperm donation.

The sperm bank market in Asia Pacific holds immense opportunities owing to a high rate of infertility and miscarriages in the region. In China, For instance, the alarming levels of air pollution in China have caused a decrease in sperm quality, count, and motility, thereby driving the demand for sperm donors and sperm banks.

Global Sperm Bank Market: Vendor Landscape Assessment

The vendor landscape of the global sperm bank is consolidated to an extent, considering very few large players control a majority of the overall sperm bank market. New England Cryogenic Center Inc., Cryos International Sperm Bank, FairFax Cryobank, and Androcryos are currently the most prominent and dominant companies operating in the global sperm bank market. Orlando, a Florida-based Cyros International Sperm Bank, is presently one of the largest sperm banks in the world. With an additional base set up in Mumbai, India in 2008, Cryos has been approved by the U.S. Food and Drug Administration as well as the Indian Council of Medical Research. Recognizing the immense potential that the sperm bank market possesses, an increasing number of players have been undergoing continuous upgrade to withstand the competition presented by industry giants.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Full Research Report on Global Sperm Bank Market: 
http://www.transparencymarketresearch.com/sperm-bank-market.html

Wednesday 8 June 2016

Oligonucleotide Synthesis Market Analysis and Industry Key Players


Oligonucleotide Synthesis Market: Overview and Segmentation

Oligonucleotide synthesis is a procedure by which nucleic acid biomolecules with definite sequences are synthetically made. Oligonucleotide synthesis is required for various life sciences research projects, from simple molecular biology research to even broader areas such as plant and animal studies, drug development, medical diagnosis, agriculture and food industry.


The global oligonucleotide synthesis market is segmented on the basis of:
  • Products
  • End-users and
  • Applications
On the basis of product, the global oligonucleotide synthesis market is broadly classified into reagent, probe, equipment, primer and synthesized oligonucleotide. Among these segments, the synthesized oligonucleotide market segment is likely to register the highest growth rate during the forecast period, due to the increasing number of its applications in research, therapeutics and diagnostics; and increasing demand for custom oligos in these applications.

On the basis of end-users, the global oligonucleotide synthesis market is further segmented into pharmaceutical and biotech firms, academic research institutes, and diagnostic laboratory. Demand from diagnostic laboratories is likely to grow rapidly among the end user segments during the forecast period owing to the adoption of new techniques such as polymerase chain reaction, real time polymerase chain reaction, DNA microarrays and others.

On the basis of applications, the global oligonucleotide synthesis market is segmented into research, therapeutics, and diagnostics. Research applications are further segmented into sequencing, gene synthesis, polymerase chain reaction (PCR), real-time quantitative polymerase chain reaction (qPCR) and others. Therapeutics market is further segmented into antisense oligos, RNAi, and others.

Oligonucleotide Synthesis Market: Drivers

The global oligonucleotide synthesis market is driven by various factors which include:
  • Budding applications in molecular diagnostics and synthetic biology
  • Increasing research & development spending in biotech and pharmaceutical companies
  • Developing significance of RNA-interference oligos in diagnostics and therapeutics
  • Venture capital funding and government spending are additional key factors that will enhance the growth of this market. For example, the U.S. National Institutes of Health (NIH) spends approximately USD1.5 billion annually to support their oligonucleotide-based applications including manual manipulation of DNA.
On the other hand, factors such as authoritarian barriers, downward pricing pressure of therapeutic oligos, may inhibit the growth of oligonucleotide synthesis market.

Oligonucleotide Synthesis Market: Region-wise Outlook

Geographically, the global oligonucleotide synthesis market is segmented into North America, Europe, Asia-Pacific (APAC) and Rest of the World. Asia-Pacific is hovering to grow rapidly due to increase in research and development activities, increasing R&D funding and rising accessibility of synthesized oligos in the region. Several major players are establishing their oligonucleotide manufacturing services in APAC to seize market opportunity in the region. For example, in July 2013, Integrated DNA Technologies, Inc. opened an oligonucleotide manufacturing unit in Singapore to provide oligonucleotide-based products to research companies in APAC, thereby establish its trail in the APAC market. Such expansion is further expected to drive growth in the APAC oligonucleotide synthesis market in the upcoming years.

Oligonucleotide Synthesis Market: Key Players

Some of the key global market participants present in the Oligonucleotide Synthesis Market are Qiagen, GE Healthcare, BioAutomation Corporation, Glen Research, Eurofins Genomics, Integrated DNA Technologies, Inc., Thermo Fisher Scientific, Inc., Link Technologies, Ltd., Nitto Denko Avecia, Inc., TriLink Biotechnologies, Inc., Agilent Technologies, Inc., GenScript USA Inc., BioSearch Technologies, Inc., Eurogentec, Sigma-Aldrich Co. LLC, Gene Link, Inc., and GeneDesign, Inc. Competitiveness in the global oligonucleotide synthesis market has been growing continually and more and more companies have been moving into the niche Oligonucleotide market, resulting in price pressure  Qiagen  lately decided to trade off its nucleic acid synthesis unit because of these pricing pressures, but strategically retained its RNAi segment as this presented both high margin and high growth to the company.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types and applications.

Full Research Report on Global Oligonucleotide Synthesis Market: 
http://www.transparencymarketresearch.com/oligonucleotide-synthesis-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Thursday 2 June 2016

Global Market for Patient Warming Devices to Register 5.20% CAGR between 2015 and 2020

Transparency Market Research has recently announced the publication of a new market research study made available on the company website. The research study, titled “Patient Warming Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2015 - 2023,” provides a detailed analysis of the market, including an overview, product portfolio, key geographical segments, and competitive landscape. The market drivers, barriers, and present trends of the market have also been discussed in the research report.According to the research study, in 2014, the global patient warming devices market was worth US$1.6 bn and is estimated to reach a value of US$2.6 bn by the end of 2023. The market is projected to register a 5.20% CAGR between 2015 and 2023.

Get a Free Sample Report: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7877
 
Hypothermia is considered as one of the major causes of death in patients who are severely wounded. In this condition, rewarming is a crucial challenge, especially for those who need angiographic or operative intervention. Patient warming devices benefit patients extensively and help them in tolerating the unintended loss of heat in the body by aiding them in achieving normal body temperatures, resulting in faster recovery. The increasing availability of technologically advanced devices and increasing awareness regarding the use of these devices are some of the factors that are estimated to drive the global market in the near future.

By product type, the global market for patient warming devices has been categorized into intravascular warming systems, surface warming systems, and patient warming accessories. In 2014, surface warming systems dominated the market, accounting for a 75% share in the overall patient warming devices market. However, the intravascular warming system segment is estimated to witness rapid growth in the next few years.

By application, the global market for patient warming devices has been classified into perioperative care, newborn care, acute care, and others. In 2014, the perioperative care segment dominated the overall market, accounting for a 40% share in the global market. This segment is projected to remain in its leading position in the forecast period. On the other hand, the acute care segment is gaining traction due to the high demand for acute care centers across the globe.

By geography, the global market for patient warming devices has been divided into Europe, North America, Latin America, the Middle East and Africa, and Asia Pacific. In 2014, North America held the largest share in the overall market owing to the increasing number of surgeries, technological advancements, high awareness levels, and well-established health care infrastructure in the region. North America is followed by Europe and Asia Pacific. The increasing geriatric population in developed countries in Europe is projected to fuel the growth of the market throughout the forecast period. Furthermore, the Asia Pacific market is estimated to grow rapidly owing to the increasing prevalence of cardiovascular and other disorders.

Furthermore, the research study talks about the competitive landscape of the global market for patient warming devices. Detailed profiles of the major players have been discussed in the scope of the research study. Some of the prominent players operating in the market are ZOLL Medical Corporation, Covidien plc, Smiths Medical, C. R. Bard, Inc., Philips Healthcare, Stryker Corporation, Inspiration Healthcare, 3M Health Care, and GE Healthcare.

Full Research Report on Global Patient Warming Devices Market: 
http://www.transparencymarketresearch.com/patient-warming-devices-market.html